Watch our CEO Henrik Blou explain Gubra’s hybrid business model and how we operate in either of these two video presentations. One is in Danish, and one is in English.
Gubra specialises in peptide-based drug discovery within metabolic and fibrotic diseases. We consist of two business areas: A contract research organisation (CRO) where we deliver research services to our customers; and a discovery business (Discovery & Partnerships) where we work on our own ideas, mature them into projects that we then partner with established pharma companies.
Together, these two business areas make up a unique whole generating steady turnover and earnings, combined with earnings with the potential for significant milestone payments and royalties.
Learn more about Gubra
Watch our CEO Henrik Blou explain all this and much more on what we do and how we operate in either of these two video presentations. One is in Danish, and one is in English.
Life Science Investor konference, Copenhagen Maj 31, 2023
Presented by Økonomisk Ugebrev
Note that the video begins in Danish, but very quickly they switch to English.
Presented by ABGSC Life Science Summit, May 30-31, 2023